Every Form 4 that Greenwich Lifesciences Inc (GLSI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GLSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GLSI filings page.
Snehal Patel, CEO, CFO and more than 10% owner of Greenwich LifeSciences, bought a total of 2,200 shares of common stock in open-market purchases on July 28–29, 2026, at prices of $13.10 and $13.59 per share. The purchases are reported as directly owned and not under a Rule 10b5-1 trading plan.
Greenwich LifeSciences, Inc. director, CEO and CFO Snehal Patel purchased 1,500 shares of common stock on July 27, 2026 at $13.62 per share in a transaction described as a purchase in open market or private transaction, increasing his direct ownership to 5,609,202 shares. The transaction was not reported as pursuant to a Rule 10b5-1 trading plan.
Greenwich LifeSciences CEO, CFO and 10% owner Snehal Patel purchased a total of 3,600 shares of Common Stock in two reported transactions, buying 2,500 shares at $13.14 per share on July 23, 2026 and 1,100 shares at $12.88 per share on July 24, 2026, all recorded as direct ownership.
Greenwich LifeSciences, Inc. director, CEO and CFO Snehal Patel, who is also a 10% owner, reported buying additional company stock. On January 13, 2026, he purchased 1,800 shares of common stock at a price of $29.83 per share. Following this open-market purchase, he beneficially owns 5,604,102 common shares, held in direct ownership.
Greenwich LifeSciences insider activity: Snehal Patel, who serves as CEO, CFO, director and a 10% owner of Greenwich LifeSciences, Inc., reported buying additional company stock. On 01/12/2026, he purchased 2,900 shares of common stock in an open market transaction coded as a "P" transaction at a price of $27.54 per share.
Following this purchase, Patel directly beneficially owned 5,602,302 shares of Greenwich LifeSciences common stock. The filing reflects direct ownership, with no indirect ownership reported in this transaction.
Greenwich LifeSciences, Inc. (GLSI) reported a Form 4 showing that CEO, CFO, director and 10% owner Snehal Patel received a grant of 100,000 stock options on 11/13/2025. These options have an exercise price of $8.2 per share and are exercisable into 100,000 shares of common stock, with an expiration date of 11/13/2035. Following this grant, Patel beneficially owns 2,347,462 derivative securities directly.
Greenwich LifeSciences (GLSI) reported an insider open‑market purchase. Snehal Patel acquired 10,600 shares of common stock at $8.43 on 11/07/2025. After this transaction, his beneficial ownership stands at 5,583,502 shares, held directly.
Patel is the company’s CEO, CFO, a director, and a 10% owner. The report reflects one reporting person and lists the transaction in Table I; no derivative transactions are shown in Table II.
Greenwich LifeSciences (GLSI): Insider purchase reported. CEO, CFO and Director Snehal Patel, a 10% owner, bought 2,300 shares of common stock on 10/31/2025 at $9.26 per share. Following this transaction, he beneficially owned 5,572,902 shares, reported as direct ownership.